This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pathology & Laboratory Medicine  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Planning for the Long Term

Roy M. Gulick, MD, MPH

JAMA. 1998;279:957-959.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Significant progress has been made in the development of effective antiretroviral drug regimens for the treatment of human immunodeficiency virus (HIV) disease. Combinations of antiretroviral agents have been shown to decrease HIV RNA levels to the limit of detection of current viral load assays in a majority of patients for periods of months to years. These profound reductions in viral load reflect significant decreases in viral replication and appear to limit the emergence of resistant viral phenotypes, thereby promoting durable antiretroviral responses.

Examples of current effective combination antiretroviral regimens with sustained responses include 3-drug combinations of 2 nucleoside analogue reverse transcriptase inhibitors and a potent HIV protease inhibitor—indinavir,^1-2 nelfinavir,³ or ritonavir⁴ and the double protease inhibitor combination of saquinavir and ritonavir.⁵ In this issue of JAMA, Montaner and colleagues⁶ report on an effective combination of reverse transcriptase inhibitors—2 nucleoside analogues and a nonnucleoside analogue—based . . . [Full Text of this Article]

From the Division of International Medicine and Infectious Diseases, New York Hospital–Cornell Medical Center, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Nevirapine, Didanosine, and Zidovudine for Patients With HIV: The INCAS Trial
Patrick G. Clay, R. Chris Rathbun, Leonard N. Slater, Richard Haubrich, Douglas Richman, Benjamin Weinstein, Julio S. G. Montaner, and David Hall
JAMA. 1999;281(2):130-131.
EXTRACT | FULL TEXT  

RELATED ARTICLE

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial
Julio S. G. Montaner, Peter Reiss, David Cooper, Stefano Vella, Marianne Harris, Brian Conway, Mark A. Wainberg, D. Smith, Patrick Robinson, David Hall, Maureen Myers, Joep M. A. Lange, and for the INCAS Study Group
JAMA. 1998;279(12):930-937.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Modified Directly Observed Therapy for Treatment of Human Immunodeficiency Virus
Mitty et al.
JAMA 1999;282:1334-1334.
FULL TEXT  

Nevirapine, Didanosine, and Zidovudine for Patients With HIV: The INCAS Trial
Clay et al.
JAMA 1999;281:130-131.
FULL TEXT  

Three Drugs, No PI
AIDS Clin Care 1998;1998:6-6.
FULL TEXT